BioGenCell

Company Overview

Snapshot

Founded in December 2008 by Yael Porat, Eyal Peleg, and Michael Belkin, BioGenCell operates with 11–50 employees. The company has secured funding across four rounds from Marius Nacht and Michael Dezer. In May 2022, BioGenCell raised a Seed round led by Marius Nacht.

Business overview

BioGenCell is a Health Tech & Life Sciences company developing cellular therapies for degenerative diseases, focusing on blood flow problems in the limbs caused by diabetes and heart disease. The company's core technology creates autologous cells derived from patients to facilitate self-repair. Its lead product, BC1, targets blood vessel insufficiency in diabetic patients. BioGenCell's patented platform supports rapid manufacturing and long-term storage of therapeutic cellular products, aiming to treat a range of conditions including diabetes, heart failure, stroke, blindness, cancer, and immunological diseases. The company operates within the Pharma & Medical Biotechnology sector, specifically Drugs Discovery & Development, and serves healthcare providers, patients, and laboratories.

Strategic signal

In December 2024, BioGenCell received FDA Fast Track Designation with expanded access for BGC101. This designation signals significant regulatory validation for its lead product, BGC101, accelerating its path to market and indicating a strong potential for addressing unmet medical needs in microvascular diseases. For investors, this represents a critical de-risking event and a strong indicator of future commercial viability and strategic momentum.

Company Intelligence Q&A

What is BioGenCell's primary focus?

BioGenCell is focused on developing cellular therapies for degenerative diseases, utilizing a platform that creates autologous cells from patients to repair damaged tissues.

When was BioGenCell founded and by whom?

BioGenCell was founded in December 2008 by co-founders Yael Porat, Eyal Peleg, and Michael Belkin.

What was a significant funding event for BioGenCell?

In May 2022, BioGenCell raised a Seed funding round, which was led by Marius Nacht.

Has BioGenCell received any grants?

In May 2019, BioGenCell received a grant from the Service Public of Wallonia, DGO6.

What recent regulatory milestone did BioGenCell achieve?

In December 2024, BioGenCell received FDA Fast Track Designation with expanded access for its product BGC101, aimed at treating microvascular diseases.